Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 685509 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 06 May 2016
At a glance
- Drugs BI 685509 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 03 May 2016 Status changed from recruiting to completed.
- 04 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 03 Mar 2016 New trial record